VBL Therapeutics Announces Last Patient Out in Phase 2 Clinical Studies of VB-201 in Psoriasis and Ulcerative Colitis

VBL Therapeutics VBLT, a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced that it has achieved completed dosing of the last patient in both of its Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound VB-201 for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015. "We are excited to announce the last patients out of our two Phase 2 clinical trials, as this represents an important milestone in the development of our Lecinoxoid molecules for the treatment of chronic inflammatory diseases," said Dror Harats, M.D., chief executive officer of VBL. "We are hopeful that these studies support the potential of our novel approach, and confirm the promising safety and efficacy data shown to date. We look forward to reporting top line data from these studies in the months ahead." The Phase 2 clinical trial in patients with psoriasis is a randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis, designed to evaluate the safety and efficacy of VB-201. Patients received 24 weeks of daily oral administration of 80 mg or 160 mg VB-201. This is the second Phase 2 clinical trial for VB-201 in psoriasis. In earlier studies, VB-201 (administered at daily doses of 20 or 80 mg) was well-tolerated and showed statistically significant improvements across multiple measures of disease severity over a twelve-week period. Disease measures continued to improve throughout the study and did not reach a plateau at the study's conclusion. Additional information regarding this study is available at: http://clinicaltrials.gov/ct2/show/NCT01837420. The Phase 2 clinical trial in patients with ulcerative colitis is a randomized, double-blind, placebo-controlled study in patients with mild to moderate ulcerative colitis, also designed to evaluate the safety and efficacy of VB-201. Patients received 24 weeks of daily oral administration of 160 mg VB-201. Additional information regarding this study is available at: http://clinicaltrials.gov/ct2/show/NCT01839214.